Notice bibliographique
Résumé
The authors of this trial1 are to be commended for evaluating an important clinical question relating to the reliability and first-dose efficacy of vardenafil in a large, placebo-controlled cohort of men with moderate-to-severe erectile dysfunction. This study provided evidence of both excellent reliability (the ability of the drug to consistently enhance erectile function time after time in an individual) and first-dose efficacy. Reading this report, one is struck quickly by a near 80% Sexual Encounter Profile question 3 (SEP3) result (the ability to get and keep the erection until the end of the sexual event) during the 12-week phase in a group of men with significant rates of dyslipidemia, diabetes and hypertension. To the casual observer, these values may seem surprisingly high, compared with other large, multicentre, placebo-controlled trials involving any of the phosphodiesterase type 5 (PDE5) inhibitors. In fact, when one looks at the study design, where only responders were entered into the 12-week placebo phase of the study, these results seem more in keeping with other trials. In addition, close to 80% of the men evaluated in this trial had previously used sildenafil, with 9% having previously tried tadalafil. It is unclear to me from this report whether non-response to other PDE5 inhibitors was an exclusion to entry into this study. If it was, these men would all be PDE5 inhibitor responders, and as such, the men evaluated in this report would represent a significantly enriched population. A more robust study design would clearly have evaluated PDE5 inhibitor–naive patients. Finally, the use of SEP question 2 (SEP2) as the primary outcome measure should be questioned. SEP2 (the ability to penetrate your partner) is, in my opinion, often positive among men who, although able to penetrate, cannot complete the sex act, lose their rigidity before orgasm and frequently express dissatisfaction with the drug. In essence, a positive SEP2 result means little clinically. Importantly, however, the authors provide robust secondary end points that demonstrate strong efficacy throughout the 12-week study period, using SEP3 and reliability measures that are clearly superior to the placebo arm. Is this a perfect study? No. It included vardenafil-naive patients but allowed men who had tried the other PDE5 inhibitors. It chose a weak primary outcome measure and studied what appears to be a responder population. Does that mean we learn nothing from it? No. This study, in support of an earlier publication, RELY 1,2 comprises part of a vast and growing literature that supports PDE5 inhibitors as safe and effective agents for men with erectile dysfunction. First-dose efficacy is an important attribute, as is reliability for the men who use these drugs, and for their partners. I generally tell my patients they're likely to have a success rate of 70%–80%, meaning that 7–8 of 10 men will respond on the first attempt and on 7–8 out of 10 subsequent attempts. This study says I am not far off for vardenafil, using 20 mg in this population of men with significant comorbid conditions.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,011 | 0,002 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; les deux têtes enseignantes s’accordent sur ce qui est montré ici.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».